Here are the 10-K annual reports from Revium Recovery Inc (RVRC) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow RVRC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RVRC filings page.
Revium Rx files its annual report describing a shift into pre‑clinical nanoparticle‑based biopharmaceuticals, centered on infectious diseases, oncology and vaccines. The company reported an aggregate market value of common equity held by non‑affiliates of about $14.3 million as of June 30, 2025 and had 61,321,100 common shares outstanding as of March 30, 2026.
Its lead asset, Nano‑Mupirocin, is a liposomal formulation of the antibiotic mupirocin being developed for severe antimicrobial‑resistant infections, supported by multiple animal studies and composition‑of‑matter patents lasting to 2035. A second candidate, Nano‑Candesartan, targets solid tumors such as pancreatic cancer as part of combination therapy, while a separate Liposomal Protein‑Loaded Technology platform is being explored for vaccines against viruses like COVID‑19 and West Nile. All programs remain pre‑clinical and will require substantial additional funding, partnerships and regulatory success.